Page 1

Autolus Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress May 6 , 2021 - Conference call to be held on May 6 , 2021 at 8:30 am ET / 1 : 30 pm BST - LONDON , May 06 , 2021 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc ( Nasdaq : AUTL ) , a clinical - stage biopharmaceutical company developing next - generation programmed T cell therapies , today announced its operational and financial results for the quarter ended March 31 , 2021 . " We have had a productive first quarter and are on track for multiple clinical read outs during the remainder of this year and into 2022 , " said Dr. Christian Itin , chief executive officer of Autolus . " We are excited by the unique characteristics of AUTO1 and encouraged by what we believe is the significant clinical benefit AUTO1 can offer for patients with relapsed / refractory ( r / r ) Acute Lymphoblastic Leukemia ( ALL ) . AUTO1 is being evaluated in the P1b / 2 FELIX study in adult ALL patients with data expected in 2022. In addition , AUTO1 is being explored in patients with B - NHL and in primary CNS lymphoma , and we are also evaluating AUTO1 / 22 in pediatric ALL patients . Finally , several programs are expected to enter the clinic in 2021 , including our next generation program AUTO6NG in Neuroblastoma , setting up clinical news flow for 2022 and beyond . " Key Pipeline Updates : • AUTO1 in relapsed / refractory ( r / r ) adult B - Acute Lymphocytic Leukemia ( ALL ) . • The International Nonproprietary Name ( INN ) name ( obecabtagene autoleucel , or obe - cel ) was published . • Autolus received PRIority Medicines ( PRIME ) designation from the European Medicines Agency ( EMA ) for AUTO1 being investigated in the ongoing FELIX Phase 1b / 2 clinical trial in ALL . This designation is designed to accelerate the review of a promising therapy targeting unmet medical need . Data from this potentially pivotal program is expected in 2022 , which , if positive , could enable us to file for accelerated approval . • AUTO1 in indolent B cell Non - Hodgkin Lymphoma ( NHL ) ( cohort 1 ) , high grade B - NHL ( cohort 2 ) and chronic lymphocytic leukemia ( CLL ) ( cohort 3 ) . o The trial is progressing well and Autolus will present updated data at the European Hematology Association ( EHA ) Congress in June 2021 . • AUTO4 in Peripheral T Cell Lymphoma ( PTCL ) . o Autolus received innovative licensing and access pathway ( ILAP ) designation from the UK Medicines and Healthcare products Regulatory Agency ( MHRA ) for AUTO4 , which is currently being studied in a Phase 1 clinical trial in PTCL . As with the AUTO1 PRIME designation , this is intended to accelerate the review of a promising therapy targeting unmet medical need . Autolus expects to provide a next data update in the second half of 2021 . • Partnerable Coronavirus Disease ( COVID - 19 ) Project . Autolus ' research team has developed a potentially universal SARS - CoV2 decoy receptor with virus neutralizing activity against SARS - CoV2 and its variants and also active against SARS - CoV1 . Operational Highlights : • In the first quarter of 2021 , Autolus sold an aggregate of 1,718,506 ADSS in offerings under its Open Market Sales Agreement SM with Jefferies LLC , for net proceeds of approximately $ 15.3 million . • Successful closing of a follow - on public offering raising net proceeds to Autolus , after underwriting discounts and offering expenses , of $ 106.9 million in February 2021 , taking total net cash raised in Q1 2021 to approximately $ 122.2 million . • As announced in Autolus ' business update in January 2021 , Autolus has realigned its research and development resources to prioritize the AUTO1 program and plans to partner the AUTO3 program before progressing it into the next phase of development . • Also announced in Autolus ' business update in January 2021 , the company adjusted its workforce and infrastructure footprint , including an overall reduction in headcount of approximately 20 % . Autolus expects to realize cash savings , on an annualized basis , of approximately $ 15 million with the operational changes fully implemented .